BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Thyroid cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Prognosis
33 results:

  • 1. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
    He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
    Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
    Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
    Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
    [TBL] [Abstract] [Full Text] [Related]  

  • 3.
    Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
    Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary thyroid cancer.
    Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
    Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the thyroid and Advances in Management.
    Nguyen M; He G; Lam AK
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Whole-genome Sequencing of Follicular thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
    Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
    J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The Integrated Analyses of Driver Genes Identify Key Biomarkers in thyroid cancer.
    Xu Q; Song A; Xie Q
    Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Foundation One Genomic Interrogation of thyroid cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
    Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary thyroid cancer.
    Masoodi T; Siraj AK; Siraj S; Azam S; Qadri Z; Albalawy WN; Parvathareddy SK; Al-Sobhi SS; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
    Thyroid; 2020 Jan; 30(1):42-56. PubMed ID: 31668133
    [No Abstract]    [Full Text] [Related]  

  • 11. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated thyroid cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
    Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
    Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
    Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
    Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
    [No Abstract]    [Full Text] [Related]  

  • 13. Mutation profiles of follicular thyroid tumors by targeted sequencing.
    Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
    Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Comprehensive Genetic Analysis of Follicular thyroid Carcinoma Predicts prognosis Independent of Histology.
    Nicolson NG; Murtha TD; Dong W; Paulsson JO; Choi J; Barbieri AL; Brown TC; Kunstman JW; Larsson C; Prasad ML; Korah R; Lifton RP; Juhlin CC; Carling T
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2640-2650. PubMed ID: 29726952
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting.
    Giannini R; Ugolini C; Poma AM; Urpì M; Niccoli C; Elisei R; Chiarugi M; Vitti P; Miccoli P; Basolo F
    Thyroid; 2017 Oct; 27(10):1267-1276. PubMed ID: 28679352
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Molecular Pathology of Anaplastic thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
    Jung SH; Kim MS; Jung CK; Park HC; Kim SY; Liu J; Bae JS; Lee SH; Kim TM; Lee SH; Chung YJ
    Oncotarget; 2016 Oct; 7(43):69638-69648. PubMed ID: 27626165
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma.
    Lin Y; Yang H; Cai Q; Wang D; Rao H; Lin S; Long H; Fu J; Zhang L; Lin P; Xu G; Rong T; Xiong X; Ma G; Liang Y
    Am J Clin Oncol; 2016 Jun; 39(3):215-22. PubMed ID: 25068469
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.